472809-12-4

Upstream product

• 5106-98-9 4-chlorosalicylic acid 
• 75-03-6 ethyl iodide 
• 64-67-5 diethyl sulfate 

Downstream Products

• 869088-31-3 (4-chloro-2-ethoxyphenyl)methanol 
• 910572-87-1 5-bromo-4-chloro-2-ethoxy-benzoic acid ethyl ester 
• 939983-32-1 5-tert-butylsulfamoyl-4-chloro-2-ethoxybenzoic acid 
• 939983-30-9 5-tert-butylsulfamoyl-4-chloro-2-ethoxybenzoic acid methyl ester 
• 1610829-45-2 rac-4-[(4S,5R)-2-(4-chloro-2-ethoxy-5-methanesulfonylphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one 
• 1610830-42-6 4-chloro-2-ethoxy-5-methanesulfonylbenzoyl chloride 
• 1235487-67-8 4-chloro-2-ethoxy-5-methanesulfonylbenzoic acid 
• 939983-31-0 4-chloro-5-chlorosulfonyl-2-ethoxybenzoic acid 

Relevant academic research and scientific papers

Novel Imidazolines as dual inhibitors of MDM2 and MDMX

Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2 and R3 are as described in this application, and methods of using the compounds

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.

4,4,5,5, Tetrasubstituted imidazolines

There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.

NOVEL COMPOUNDS

A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1 is H, C1-6alkyl, -C(A)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-Cl-4alkyl, wher

Novel compounds

The present invention provides compounds of Formula I wherein R1, R2, R3, and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment